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Age-related macular degeneration (ARMD) and diabetic retinopathy (DR) are the leading causes of visual loss in industrialized nations. Vision loss in these disorders results from abnormal choroidal retinal neovascularization. Because the retina consists of well-defined layers of neuronal, glial and vascular elements, relatively small disturbances, such as those seen with vascular proliferation or edema, can lead to significant loss of visual function. Inherited retinal degeneration, such as retinitis pigmentosa (RP), is also associated with vascular abnormalities such as arteriolar narrowing and vascular atrophy. Although significant progress has been made in identifying factors that promote and inhibit angiogenesis, no treatment is currently available to specifically treat ocular vascular diseases.
In the normal adult circulation and bone marrow (BM) there is a population of stem cells from which different sub-populations of cells can differentiate along hematopoietic (Lin + ) or nonhematopoietic (Lin -) lineages. Furthermore, the Lin -hematopoietic stem-cell (HSC) population contains endothelial precursor cells (EPCs) capable of forming blood vessels in vitro and in vivo 1 . These cells can participate in normal and pathological postnatal angiogenesis [2] [3] [4] as well as differentiate into a variety of non-endothelial cell types including hepatocytes 5 , microglia 6 , cardiomyocytes 7 and epithelium 2 . Although these cells have been used in several experimental models of angiogenesis, the mechanism of EPC targeting to neovasculature is unknown and there is no strategy that can effectively increase the number of cells that contribute to a particular vasculature. Here we show that intravitreal injection of Lin -HSCs from BM selectively target activated retinal astrocytes. These cells also extensively incorporate into developing retinal vessels and remain stably incorporated into neovasculature of the mouse eye for at least two months after injection. We also show that these same cells can be used to rescue and stabilize degenerating retinal vasculature in a mouse model of retinal degeneration. Using a physiologically relevant neonatal mouse model of retinal angiogenesis, we selectively targeted neovasculature and inhibited new vessel formation without affecting pre-established vessels using a cell-based gene therapy. Because most diseases that cause vision loss involve abnormal angiogenesis, Lin -HSCs or EPCs may prove useful for modulating abnormal bloodvessel growth in ARMD, DR and certain retinal degenerations associated with abnormal vasculature.
An astrocytic template guides retinal angiogenesis
During development of the murine retinal vasculature, ischemiadriven retinal blood vessels develop in close association with astrocytes. These glial elements migrate onto the neonatal retina from the optic disc along the ganglion cell layer and spread radially; a similar process occurs in the third-trimester human fetus. As the murine retinal vasculature develops, endothelial cells use this already established astrocytic template to determine the retinal vascular pattern ( Fig. 1a and b) 
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. At birth, retinal vasculature is virtually absent. By postnatal day 14 (P14), the retina has developed complex primary (superficial) and secondary (deep) layers of retinal vessels coincident with the onset of vision. Initially, spokelike peripapillary vessels grow radially over the pre-existing astrocytic network towards the periphery, becoming progressively interconnected by capillary plexus formation. These vessels grow as a monolayer within the nerve fiber through P10 (Fig. 1a) . Between P7 and P8, collateral branches begin to sprout from this primary plexus and penetrate into the retina to the outer plexi- 
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form layer where they form the secondary, or deep, retinal plexus. By P21, the entire network undergoes extensive remodeling and a tertiary, or intermediate, plexus forms at the inner surface of the inner nuclear layer (Fig. 1b) .
A neonatal mouse retinal angiogenesis model has been used to study the role of HSCs during ocular angiogenesis for several reasons. In this physiologically relevant model, a large astrocytic template exists prior to the appearance of endogenous blood vessels, permitting an evaluation of the role for cell-cell targeting during physiologically relevant angiogenesis. In addition, this consistent and reproducible neonatal retinal vascular process is known to be hypoxia-driven; in this respect, it has similarities to many retinal diseases in which ischemia is known to be involved. (Fig. 1c) . Accepted EPC markers like Flk1, Tie2 and Sca1 were poorly expressed and not used for further fractionation.
Enrichment of EPCs from BM

Lin
-HSCs contain EPC that target astrocytes We investigated whether intravitreally injected HSCs could target specific cell types of the retina and participate in retinal angiogenesis. Approximately 1 × 10 5 Lin -or Lin + HSCs isolated from BM of adult green fluorescent protein (GFP)-or LacZ-transgenic mice were injected into postnatal day 2 (P2) mouse eyes. Four days after injection (P6), many Lin -HSCs from GFP-or LacZ-transgenic mice were adherent to the retina and had the characteristic elongated appearance of endothelial cells (Fig. 2a) . In many areas, the GFPexpressing cells were arranged in a pattern conforming to underlying astrocytes and resembled blood vessels. These fluorescent cells were observed ahead of the endogenous, developing vascular network (Fig. 2b) . In contrast, only a small number of Lin + HSCs (Fig.  2c) or adult mouse mesenteric endothelial cells (Fig. 2d) attached to the retinal surface. To determine whether injected HSCs could also attach to retinas with pre-established vessels, we injected Lin -HSCs into adult eyes. Notably, no cells attached to the retina or incorporated into established, normal retinal blood vessels (Fig. 2e) .
To determine the relationship between injected Lin -HSCs and retinal astrocytes, we used a transgenic mouse expressing glial fibrillary acidic protein (GFAP) promoter-driven GFP. Retinas of the GFAP-GFP-transgenic mice injected with Lin -HSCs from these enhanced GFP (eGFP) transgenic mice showed colocalization of the injected eGFP EPCs and existing astrocytes ( Fig. 2f-h, arrows) . Processes of eGFP + Lin -HSCs conformed to the underlying astrocytic network (Fig. 2g) . In P2 eyes of GFAP-GFP-transgenic mice, the injected, labeled cells attached to only astrocytes; in P6 mouse retinas, where the retinal periphery also does not yet have endogenous vessels, injected cells adhered to astrocytes in these unvascularized areas. Notably, injected, labeled cells were observed in deeper layers of the retina at the precise location where normal retinal vessels will subsequently develop (Fig. 2i, arrows) .
To determine whether injected Lin -HSCs are stably incorporated into the developing retinal vasculature, we examined retinal vessels at several later time points. As early as P9 (7 d 
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(14 d after injection), the cells were already extensively incorporated into retinal vascular-like structures (Fig. 2k) . When rhodamine-dextran was injected intravascularly (to identify functional retinal blood vessels) prior to collecting globes, most Lin -HSC were aligned with patent vessels (Fig. 2l) . We observed two patterns of labeled-cell distribution: first, cells were interspersed along vessels in between unlabeled endothelial cells; and in the second pattern, vessels were composed entirely of labeled cells. Injected cells were also incorporated into vessels of the deep vascular plexus (Fig. 2m) . Although sporadic incorporation of HSC-derived EPC into neovasculature has been reported 1, 2 , these vascular networks are entirely composed of such cells. This demonstrates that cells from a population of BM-derived Lin -HSCs injected intravitreally can efficiently incorporate into any layer of the forming retinal vascular plexus. Histological examination of non-retinal tissues (for example, brain, liver, heart, lung and BM) did not demonstrate the presence of any GFP + cells when examined up to 5 or 10 days after intravitreal injection (data not shown).
These observations suggest that a sub-population of cells within the HSC Lin -fraction selectively home to retinal astrocytes and stably incorporate into developing retinal vasculature. Because these cells have many characteristics of endothelial cells (association with retinal astrocytes, elongated morphology, stable incorporation into patent vessels and absence from extravascular locations), we believe these cells represent EPCs present in the Lin -HSC population. The targeted astrocytes are the same cell type observed in many of the hypoxic retinopathies, and glial cells are a prominent component of neovascular fronds observed in DR and other forms of retinal injury [9] [10] [11] [12] . Under conditions of reactive gliosis and ischemia-induced neovascularization, activated astrocytes proliferate, produce cytokines and upregulate GFAP (refs. 9,13-15), in a similar manner to neonatal retinal vascular template formation in many mammalian species, including humans 16 .
To test whether Lin -HSCs target activated astrocytes in adult mouse eyes as they do in neonatal ones, we injected Lin -HSC into adult eyes with retinas injured by photocoagulation (Fig. 3a) or needle tip (Fig. 3b) . In both models, a population of cells with prominent GFAP staining occurred only around the injury site ( Fig. 3a and b) . Injected Lin -HSCs localized to the injury site and remained specifically associated with GFAP + astrocytes ( Fig. 3a  and b) . At these sites, Lin -HSCs were also observed to migrate (Fig. 2e) . These data suggest that Lin -HSCs can selectively target activated glial cells in injured adult retinas with gliosis, as well as neonatal retinas undergoing vascularization.
Lin
-HSCs can rescue and stabilize degenerating vasculature As intravitreally injected Lin -HSC target astrocytes and incorporate into the normal retinal vasculature, these cells may stabilize degenerating vasculature in ischemic or degenerative retinal diseases associated with gliosis and vascular degeneration. To test this hypothesis, we used the rd/rd mouse, a model for retinal degeneration that shows marked degeneration of photoreceptor and retinal vascular layers by one month after birth. The retinal vasculature in these mice develops normally until P16 at which time the deeper vascular plexus regresses; in most mice, the deep and intermediate plexuses are nearly completely degenerated by P30. To determine whether HSCs can rescue the regressing vessels, we injected Lin + or Lin -HSCs from BALB/c mice into rd/rd mice intravitreally at P6. By P33, after injection with Lin + cells, vessels of the deepest retinal layer were nearly completely absent ( Fig. 4a and b) . In contrast, most Lin -HSC-injected retinas have a nearly normal retinal vasculature by P33, with three parallel, well-formed vascular layers ( Fig. 4c and  d) . Quantification of this effect showed that the average length of vessels in the deep vascular plexus of Lin -injected rd/rd eyes was nearly three times greater than in untreated or Lin + cell-treated eyes (Fig. 4e) . Injection of Lin -HSC from rd/rd adult mouse (FVB/N) BM also rescued degenerating rd/rd neonatal mouse retinal vasculature (Fig. 4f) . Degeneration of the vasculature in rd/rd mouse eyes occurred as early as 2-3 weeks postnatally. Injection of Lin -HSC as late as P15 also resulted in partial stabilization of the degenerating vasculature in the rd/rd mice for at least one month ( Fig. 4g and h) . 
-HSC injected into younger (P2) rd/rd mice also incorporate into the developing superficial vasculature (data not shown). By P11, these cells migrated to the level of the deep vascular plexus and formed a pattern identical to of the wild-type outer retinal vascular layer (Fig. 5a ). To more clearly describe the manner in which injected Lin -HSC incorporate into, and stabilize, degenerating retinal vasculature in the rd/rd mice, we injected Lin -HSCs of BALB/c mice into Tie2-GFP FVB mouse eyes. The FVB mice have the rd/rd genotype, and because they express the fusion protein Tie2-GFP, all endogenous blood vessels are fluorescent. If non-labeled Lin -HSCs are injected into neonatal Tie2-GFP FVB eyes and are subsequently incorporated into the developing vasculature, there should be non-labeled gaps in the endogenous, Tie2-GFP labeled vessels that correspond to the incorporated, non-labeled Lin -HSCs that were injected. Subsequent staining with another vascular marker (CD31) should delineate the entire vessel and show whether non-endogenous endothelial cells are part of the vasculature. Two months after injection, we found CD31-positive, Tie2-GFP-negative vessels in the Lin -HSC-injected retinas (Fig. 5b) . Most rescued vessels contained Tie2-GFP positive cells (Fig. 5c) . The distribution of pericytes, as determined by staining for α-smooth-muscle actin, was not changed by Lin -HSC injection regardless of whether there was vascular rescue (Fig. 5d ). These data demonstrate that intravitreally injected Lin -HSCs migrate into the retina, participate in the formation of normal retinal blood vessels and stabilize endogenous degenerating vasculature in a genetically defective mouse.
Inhibition of retinal angiogenesis by transfected EPCs
Because most retinal vascular diseases involve abnormal vascular proliferation rather than degeneration, we determined whether EPCs targeted to astrocytes could be used to deliver an anti-angiogenic protein and inhibit angiogenesis. We transfected Lin -HSCs with T2-tryptophanyl-tRNA synthetase (T2-TrpRS). T2-TrpRS is a 43-kD fragment of TrpRS that potently inhibits retinal angiogenesis 17, 18 (Fig. 6a) . On P12, retinas injected with control plasmidtransfected Lin -HSCs on P2 had normal primary (Fig. 6c) and secondary (Fig. 6d) retinal vascular plexuses. When T2-TrpRStransfected Lin -HSCs were injected into P2 eyes and evaluated 10 days later, the primary network had significant abnormalities (Fig.  6e) , and formation of the deep retinal vasculature was nearly completely inhibited (Fig. 6f) . The few vessels observed in these eyes were markedly degenerated with large gaps between vessels. The extent of inhibition by T2-TrpRS-secreting Lin -HSCs is detailed in Supplementary Table A online. T2-TrpRS is produced and secreted by Lin -HSC in vitro (data not shown), and after injection of these cells into the vitreous, we observed a 30-kD fragment of T2-TrpRS in the retina (Fig. 6b) . This 30-kD fragment was specifically observed only in retinas injected with transfected Lin -HSCs, and this decrease in apparent molecular weight compared to the recombinant or in vitro-synthesized protein may be due to processing or degradation of the T2-TrpRS in vivo. These data indicate that Lin -HSCs can be used to deliver functionally active angiostatic molecules to the retinal vasculature by targeting activated astrocytes.
Although it is possible that the observed angiostatic effect is due to cell-mediated activity, this is seems unlikely given that eyes treated with identical but non-T2-transfected Lin -HSCs showed normal retinal vasculature.
Discussion
Our finding that intravitreally injected Lin
-HSC localize to retinal astrocytes and incorporate into vessels suggests they may be useful in treating many retinal diseases. Although most injected HSC adhere to the astrocytic template, small numbers migrate deep into the retina, homing to regions where the deep vascular network will subsequently develop. Even though no GFAP + astrocytes are observed in this area before P42 (ref. 8), this does not exclude the possibility that GFAP -glial cells are already present to provide a signal for Lin -HSC localization. Many diseases are associated with reactive gliosis 11, 13, 19 and in DR, glial cells and their extracellular matrix are associated with pathological angiogenesis [11] [12] [13] 20, 21 .
As injected Lin
-HSCs specifically attached to GFAP-expressing glial cells, regardless of the type of injury, it may be possible to use Lin -HSCs to target pre-angiogenic lesions in the retina. For example, in the ischemic retinopathies such as diabetes, neovascularization is a response to hypoxia. By targeting Lin -HSCs to sites of pathological neovascularization, it may be possible to 'stabilize' developing neovasculature, preventing abnormalities of these vessels such as hemorrhage or edema (the causes of vision loss associated with DR). This effect might, in fact, alleviate the hypoxia that originally stimulated the neovascularization. Moreover, it may be possible to effectively deliver angiostatic proteins, such as T2-TrpRS, to sites of pathological angiogenesis by using Lin -HSCs and laser-induced activation of astrocytes. Because laser photocoagulation is commonly used in clinical ophthalmology, it may be possible to use this approach for many retinal diseases. Although , their use for eye diseases may be more advantageous as intraocular injection makes it possible to deliver large numbers of cells directly to the site of disease.
We have used markers for lineage-committed hematopoietic cells to negatively select a population of BM-derived HSCs presumed to contain EPCs. Although the sub-population of BM-derived HSCs that can serve as EPCs is not characterized by commonly used cell surface markers, the behavior of these cells in a developing or injured retinal vasculature is entirely different from that of Lin + or adult endothelial-cell populations. Further subfractionation of HSC using markers such as Lin -
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+ did not reveal any substantial difference from the use of Lin -cells alone. These cells selectively target to sites of retinal angiogenesis and participate in the formation of patent blood vessels. The absence of non-targeted Lin -HSCs could be due to lack of survival by the non-EPC fraction of the total population. Whereas Lin -HSC selection appears to be effective for EPCs that target and incorporate into retinal vasculature, a different selection process may be more effective in other target tissues. Further characterization of the EPC population and the molecular mechanism of its targeting to astrocytes is needed and is currently under investigation.
Inherited retinal degenerations are often accompanied by loss of retinal vasculature 23, 24 . Effective treatment of such diseases will require restoration of function as well as maintenance of complex tissue architecture. Several recent studies have explored the use of cell-based delivery of trophic factors or stem cells themselves 25 , but some combination of both may be necessary. For example, use of growth-factor therapy to treat retinal degenerative disease resulted in unregulated overgrowth of blood vessels 26 resulting in severe disruption of the normal retinal tissue architecture. The use of neural 27 or retinal 28 stem cells to treat retinal degenerative disease may reconstitute neuronal function, but a functional vasculature will also be necessary to maintain retinal functional integrity. We show that incorporation of Lin -HSCs into the retinal vessels of rd/rd mice stabilized the degenerative vasculature without disrupting retinal structure. This rescue effect also occurred when the cells were injected into P15 rd/rd mice. Because vascular degeneration begins on P16 in rd/rd mice, this observation expands the therapeutic window for effective Lin -HSC treatment. The vascular rescue seen in this model is substantial, but it is not clear what effect, if any, Lin -HSC treatment would have on the neuroretinal degeneration typically associated with these disorders. It will be interesting to assess the effect of this treatment on visual function.
We have found that Lin -HSCs contain a population of EPCs that can promote angiogenesis by targeting reactive astrocytes and incorporate into an established template without disrupting retinal structure. Thus, genetically modified autologous EPCs transplanted into ischemic or abnormally vascularized eyes may stably incorporate into new vessels and continuously deliver therapeutic molecules locally for prolonged periods of time. Such local delivery of pharmacological agents in physiologically meaningful doses may represent a new paradigm for treating currently untreatable ocular diseases.
Methods
Cell isolation and enrichment. All experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and all experimental procedures were approved by the TSRI Animal Care and Use Committee. Bone-marrow cells were extracted from B6.129S7-Gtrosa26, Tie-2GFP, ACTbEGFP, FVB/NJ (rd/rd mice) or BALB/cBYJ adult mice (The Jackson Laboratory, Bar Harbor, Maine). Monocytes were then separated by density gradient separation using Histopaque (Sigma) and labeled with biotin conjugated lineage panel antibodies (CD45, CD3, Ly-6G, CD11, TER-119, Pharmingen, San Diego, California) for Lin -selection. Lineage positive (Lin + ) and negative (Lin -) cells were separated using a magnetic separation device, MACS (Miltenyi Biotech, Auburn, California). Cells were further characterized using a FACS Calibur (Beckton Dickinson, Franklin Lakes, New Jersey) using following antibodies: PE-conjugated-Sca1, c-kit, KDR and CD31 (Pharmingen, San Diego, California). For characterization of Tie2, we used Tie2-GFP BM cells.
To collect adult mouse endothelial cells, mesenteric tissue was surgically removed from ACTbEGFP mouse and placed in collagenase (Worthington, Lakewood, New Jersey) to digest followed by filtration using a 45-µm mesh. Flow-through was collected and incubated with endothelial growth media (Clonetics, San Diego, California). Endothelial characteristics were confirmed by observing morphological cobblestone appearance, staining with CD31 /ml) were suspended in opti-MEM (Gibco) containing stem-cell factor (Peprotech). DNA (1 µg) and FuGENE (3 µl) mixture was then added and incubated at 37 °C for 18 h. After incubation, cells were washed and collected. The transfection rate of this system was ∼17% that was confirmed by FACS analysis. T2 production was confirmed by western-blot analysis.
Immunohistochemistry and confocal analysis. Retinas were collected at various time points and were prepared for either whole mounting or frozen sectioning. For whole mounts, retinas were fixed with 4% paraformaldehyde and blocked in 50% FBS/ 20% normal goat serum for 1 h at room temperature. Retinas were processed for primary antibodies and detected with secondary antibodies. The primaries used were: anti-Collagen IV (Chemicon, Temecula, California), anti-β-gal (Promega, Madison, Wisconsin), anti-GFAP (Dako) and anti-α−smooth muscle actin (αSMA, Dako). Secondary antibodies used were conjugated either to Alexa 488 or 594 (Molecular Probes). Images were taken using the 1024 Confocal microscope (Biorad, Hercules, California). Three-dimensional images were created using Lasersharp (Biorad) to examine the three different layers of vascular development in the wholemount retina.
In vivo retinal angiogenesis quantification assay. For T2-TrpRS analysis, the primary and deep plexus were reconstructed from the three dimensional images. Primary plexus was divided into two categories: normal development or halted vascular progression. The categories of inhibition of deep vascular development were construed based upon the percentage of vascular inhibition including the following criteria: complete inhibition of deep plexus formation was labeled 'complete', normal vascular development (including less than 25% inhibition) was labeled 'normal' and the remainder labeled 'partial'. For the rd/rd mouse rescue data, 4 separate areas of the deeper plexus in each whole-mounted retina were captured using a 10× lens. The total length of vasculature was calculated for each image, summarized and compared among groups. To acquire accurate information, we injected Lin -cells into one eye and Lin + cells into another eye of the same mouse. Non-injected control retinas were taken from the same litter.
Adult retinal injury models. Laser and scar models were created using either a diode laser (150 mW, 1 s, 50 mm) or mechanically by puncturing the retina with a 27-G needle. 5 d after injury, cells were injected using the intravitreal method. Eyes were collected five days later.
Note: Supplementary information is available on the Nature Medicine website.
